As we know inflammatory bowel disease is an emergent plight in developed & developing countries. IBD is an idiopathic ulceroinflammatory condition of the bowel which may or may not have transmural stretch. IBD has two clinic pathological condition Ulcerative colitis & Crohns’s disease. In United State of America there are 1.4 million of people suffering from Ulcerative colitis. IBD has a plethora of comorbid disorders .Gastrointestinal disorder arising from cholelithiasis, cutaneous disease arising from psoriasis & metabolic disorders arising from diabetes mellitus. DPP4 which is instrumental in aggravating diabetes mellitus gets hiked in IBD too , which may have serious implications in the worsening of the latter in diabetes . Hence, in our research we probed for the anticolitic potential of a standard inhibitor of DPP4, Linagliptin to ensure the enzymes suitability as a probable target for IBD.
Keywords: IBD: Inflammatory Bowel Disease, UC: Ulcerative colitis, CD: Crohn’s diseas
